Cost-Effectiveness of Glycopyrronium Bromide Compared with Tiotropium in Patients with Chronic Obstructive Pulmonary Disease in Sweden

Applied Health Economics and Health Policy
Madlaina Costa-ScharplatzDavid Price

Abstract

The objective of this study was to compare the cost effectiveness of once-daily Seebri Breezhaler(®) (glycopyrronium bromide) 50 µg with Spiriva(®) (tiotropium bromide) 18 µg in the maintenance treatment of chronic obstructive pulmonary disease (COPD) in the Swedish setting. A previously published COPD Markov model accounting for disease progression and treatment discontinuation was used. Disease progression included the annual decline in forced expiratory volume in the first second (FEV1) and occurrence of any exacerbations. Efficacy in the model consisted of FEV1 improvement between baseline and 12 weeks and the annual risk ratio of having an exacerbation compared to placebo. These clinical efficacy inputs were derived from a 1-year head-to-head trial comparing glycopyrronium 50 µg to tiotropium 18 µg. Utility values and cost estimates were obtained from the literature. The base-case analysis was performed for a 3-year time horizon. Cost and effects were discounted with 3% in accordance to Swedish guidelines. Uncertainty was assessed by one-way and probabilistic sensitivity analyses. Glycopyrronium was found to be less costly and more effective than tiotropium in moderate to severe COPD patients with cost savings of 5197 Swed...Continue Reading

References

Oct 1, 1993·Medical Decision Making : an International Journal of the Society for Medical Decision Making·F A Sonnenberg, J R Beck
Sep 24, 2002·Respiratory Medicine·F AnderssonB Lundbäck
Dec 12, 2002·Chest·Sven-Arne JanssonBo Lundbäck
May 29, 2004·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Sixten BorgSean D Sullivan
Feb 5, 2005·Respirology : Official Journal of the Asian Pacific Society of Respirology·UNKNOWN Asia Pacific COPD Roundtable Group
May 28, 2005·Archivos de bronconeumología·A J García RuizF Martos Crespo
Feb 23, 2007·The New England Journal of Medicine·Peter M A CalverleyUNKNOWN TORCH investigators
Mar 21, 2007·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·Maureen P M H Rutten-van MölkenBrigitta U Monz
Oct 13, 2012·The European Respiratory Journal·Edward KerwinDonald Banerji
Jun 8, 2013·Drug and Therapeutics Bulletin
Oct 8, 2013·Respiratory Research·Shannon CopePaul Jones

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.